Electra Therapeutics to Present Clinical Data for ELA026 at the American Society of Hematology (ASH) 2023 Annual Meeting

Company to reveal first clinical data from Phase 1b study of ELA026, its lead product candidate for life-threatening inflammatory disease, secondary hemophagocytic lymphohistiocytosis (sHLH)

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets, announced today that the company will present the initial clinical data for its lead drug candidate, ELA026, in a poster at the American Society of Hematology (ASH) annual meeting being held in San Diego, California, December 9-12, 2023.

ELA026 is a monoclonal antibody that targets signal regulatory protein-α/β1/γ (SIRP) to enable precise depletion of pathological immune cells. ELA026 is currently in a Phase 1b clinical study in patients with secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disease.

Details of the poster presentation are as follows:

Title: A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Session Name: 201. Granulocytes, Monocytes, and Macrophages: Poster I

Session Date and Time: Saturday, December 9, 2023, 5:30 – 7:30 p.m.

Location: San Diego Convention Center, Halls G-H

Publication Number: 1162

About Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory condition for which there is no approved treatment. sHLH can be triggered by cancer, immunotherapy, infection, or an autoimmune disease. Once triggered, sHLH requires immediate intervention. Without treatment, it can rapidly progress from symptoms such as persistent fever, hepatomegaly and/or splenomegaly, and cytopenias, to multi-organ failure and death. Even with the current use of off-label treatments that have toxicity challenges and limited efficacy, sHLH remains fatal in approximately 60% of adults within 3.5 years.

About Electra Therapeutics

Electra Therapeutics is a clinical stage biotechnology company developing therapies against novel targets for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells, and precisely depletes pathological immune cells. ELA026 is in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening hyperinflammatory condition for which there is no approved treatment. For more information, please visit Electra Therapeutics and follow us at @ELECTRA_Biotech and on LinkedIn.

Contacts

Media Contact:
Kathryn Morris

The Yates Network

914-204-6412

[email protected]